Immune-related adverse events in patients with preexisting myasthenia gravis and thymoma following immune checkpoint inhibitor treatment: a retrospective, observational study - PubMed
3 hours ago
- #Myasthenia Gravis
- #Immune Checkpoint Inhibitors
- #Thymoma
- The study found that patients with preexisting myasthenia gravis and thymoma (MGT) who received immune checkpoint inhibitor (ICI) therapy all experienced grade 3 or higher immune-related adverse events (irAEs), including myocarditis, compared to thymoma patients without MG (TOMA).
- MGT patients showed symptom exacerbation, such as myasthenic crises, but those who received immunosuppressive agents before ICI therapy and steroids with intravenous immunoglobulin during irAEs had better outcomes.
- Increased anti-acetylcholine receptor antibody levels were observed one month after irAE onset, and the presence of germinal centers in thymus tissues of TOMA patients was linked to severe irAEs, suggesting a predictive biomarker.